BioVeris licenses Baxter's vaccine portfolio
|
|
BY OUR PHARMA CORRESPONDENT
13th August,2005:BioVeris Corporation has
completed a Technology License Agreement with
Baxter Healthcare Corporation for exclusive patent
rights to a broad portfolio of vaccine candidates.
Vaccines covered by the agreement include those
for the prevention of diseases caused by Group A
streptococci, Group B streptococci, Pneumococci,
Group B meningococci, anthrax bacilli and urinary
tract infection (UTI) associated E. coli, a
BioVeris release said.
Under the Agreement, BioVeris receives exclusive
rights to patents or know-how related to the
manufacture, production, use and commercialization
of the vaccine candidates. The company paid a
license issue fee and may also make additional
future payments for patent costs, milestone fees
for initiating and completing human clinical
trials and receiving regulatory approvals.
BioVeris is also required to pay royalties on
product sales and beginning in 2010, is required
to pay a minimum annual royalty that is creditable
against any other milestone payments and
royalties.
The vaccine portfolio covered by the agreement is
based on a conjugate technology platform and also
includes recombinant protein antigens. The vaccine
candidates are expected to complement and expand
the existing intellectual property and vaccine
candidates at BioVeris, which now has additionl
comprehensive candidates for vaccines against
bacterial meningitis, including that of
streptococcal, pneumococcal and meningococcal
origin.
BioVeris' vaccine candidate portfolio addresses
different organisms, including group A
streptococci (of strep throat, impetigo,
flesh-eating bacteria and streptococcal toxic
shock syndrome), group B streptococci (of sepsis,
meningitis, and pneumonia in newborns and adults),
group B meningococci (of sepsis, meningitis, and
pneumonia at any age), and E. coli (of UTI,
predominantly for women).
In addition, the vaccine candidate for disease
caused by anthrax bacilli may provide a safer and
better anthrax vaccine based on a recombinant
protective antigen. Each of these vaccines could
be candidates for entry into billion dollar global
markets.
BioVeris Corporation is a global integrated health
care company developing proprietary technologies
in diagnostics and vaccinology. BioVeris is
headquartered in Gaithersburg, Maryland.
Baxter International Inc. is a global healthcare
company with 2004 sales of 9.5 billion. With
approximately 48,000 employees, Baxter applies its
expertise in medical devices, pharmaceuticals and
biotechnology.
BY OUR PHARMA CORRESPONDENT |
|
|
